General Gastroenterology

Upadacitinib lands indication for moderately to severely active disease in adults

Even with reduced risk of necrotizing enterocolitis, adoption is slow across the U.S.

Clearly helpful in manufacturers' trials, but not so much in routine practice

Oral treatment alleviates symptoms better than placebo

Trial boosts case for label expansion

Outdone by gastroenterologists in finding adenomatous polyps

Small but clear boost to overall survival

But not a cure-all in states boosting eligibility

Intraindividual shifts over time may explain why drugs don't work the same in everyone

Contrast medium may be withheld due to sensitivity, kidney disease, or lack of availability

Clinicians found CT scan to be best diagnostic tool

Vowst approved for preventing recurrent C. difficile infections after antibiotics

Also in TTHealthWatch: chronic pain in U.S. adults, and a new treatment for C. diff

Fewer actionable mutations, less likely to meet genomic criteria for immunotherapy